公开(公告)号：US20160208255A1

公开(公告)日：2016-07-21

申请号：US14979568

申请日：2015-12-28

Applicant: Nitto Denko Corporation

Inventor： Yoshiro Niitsu ,  Kenjirou Minomi ,  Jens Harborth ,  Cima Cina ,  Kwok Yin Tsang ,  Wenbin Ying ,  Hirokazu Takahashi

IPC: C12N15/113

CPC classification number: A61B5/0071 ,  A61K31/713 ,  A61K49/0021 ,  C07D311/30 ,  C07F9/6533 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/3515 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2320/35 ,  C12N2320/53 ,  C12Q1/02 ,  G01N33/582 ,  H05K999/99 ,  C12N2310/3533 ,  C12N2310/3531 ,  C12N2310/321 ,  C12N2310/3521

Abstract: This invention provides compounds, compositions and methods for modulating the expression of human p21 using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. A nucleic acid molecule can have a) a polynucleotide sense strand and a polynucleotide antisense strand; b) each strand of the molecule being from 15 to 30 nucleotides in length; c) a contiguous region of from 15 to 30 nucleotides of the antisense strand being complementary to a sequence of an mRNA encoding p21; and d) at least a portion of the sense strand can be complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length.

Abstract translation: 本发明提供了使用RNA干扰来调节人p21的表达的化合物，组合物和方法。 RNA干扰分子可用于预防或治疗恶性肿瘤等疾病的方法。 核酸分子可具有a）多核苷酸有义链和多核苷酸反义链; b）分子的每条链长度为15至30个核苷酸; c）反义链的15至30个核苷酸的连续区域与编码p21的mRNA的序列互补; 和d）所述有义链的至少一部分可以与所述反义链的至少一部分互补，并且所述分子具有长度为15至30个核苷酸的双链体区。

公开(公告)号：US20160186183A1

公开(公告)日：2016-06-30

申请号：US14979573

申请日：2015-12-28

Applicant: Nitto Denko Corporation

Inventor： Yoshiro Niitsu ,  Kenjirou Minomi ,  Hiroki Nishita ,  Yusuke Nakashima ,  Miyono Miyazaki ,  Keiko Kajiwara ,  Jihua Liu ,  Li Wang ,  Jens Harborth ,  Bharat Majeti ,  Roger Adami ,  Wenbin Ying

IPC: C12N15/113

CPC classification number: C07F9/6533 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/3515 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2320/35 ,  C12N2320/53 ,  C12Q1/02 ,  G01N33/582 ,  H05K999/99 ,  C12N2310/3533 ,  C12N2310/3531 ,  C12N2310/321 ,  C12N2310/3521

Abstract: This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.

Abstract translation: 本发明提供了通过鉴定哺乳动物的肿瘤细胞来预防，治疗或改善与有需要的哺乳动物有关的KRAS突变相关的恶性肿瘤的一种或多种症状的方法和组合物，所述肿瘤细胞包含以下至少一种：（ i）KRAS基因的突变，和（ii）KRAS蛋白的异常表达水平; 以及向哺乳动物施用治疗有效量的包含一种或多种在降低GST-和pgr表达中有活性的RNAi分子的组合物。

公开(公告)号：US11737982B2

公开(公告)日：2023-08-29

申请号：US16377032

申请日：2019-04-05

Applicant: Nitto Denko Corporation

Inventor： Roger Adami ,  Yuwei Wang ,  Haiqing Yin ,  Liping Wang ,  Dong Liu ,  Wenbin Ying

IPC: A61K9/19 ,  C12N15/11 ,  A61K47/26 ,  A61K47/36 ,  A61K47/40 ,  A61K9/127 ,  A61K9/51 ,  A61K31/713 ,  A61K9/14 ,  C12N15/113

CPC classification number: A61K9/19 ,  A61K9/1271 ,  A61K9/145 ,  A61K9/146 ,  A61K9/5123 ,  A61K31/713 ,  A61K47/26 ,  A61K47/36 ,  A61K47/40 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/32

Abstract: This invention provides compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.

公开(公告)号：USRE49431E1

公开(公告)日：2023-02-28

申请号：US16990860

申请日：2020-08-11

Applicant: Nitto Denko Corporation

Inventor： Kenjirou Minomi ,  Hirokazu Takahashi ,  Erika Terada ,  Jens Harborth ,  Jun Zhang ,  Mohammad Ahmadian ,  Wenbin Ying

IPC: A61B5/00 ,  A61K49/00 ,  C07D311/30 ,  C07F9/6533 ,  C12N15/113 ,  C12Q1/02 ,  G01N33/58 ,  A61K31/713

Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

公开(公告)号：US20220233445A1

公开(公告)日：2022-07-28

申请号：US17658078

申请日：2022-04-05

Applicant: Nitto Denko Corporation

Inventor： Kwok Yin Tsang ,  Bharat Majeti ,  John Gaudette ,  Roger Adami ,  Hao Bai ,  Wenbin Ying

IPC: A61K9/127 ,  A61K47/10 ,  A61K47/69 ,  A61K31/7105 ,  A61K47/14 ,  C07C201/00

Abstract: Fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, compounds, compositions and methods are to provide nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.

公开(公告)号：US20220087531A1

公开(公告)日：2022-03-24

申请号：US17454757

申请日：2021-11-12

Applicant: Nitto Denko Corporation

Inventor： Yoshiro Niitsu ,  Kenjirou Minomi ,  Bharat Majeti ,  Li Wang ,  Jihua Liu ,  Roger Adami ,  Wenbin Ying

IPC: A61B5/00 ,  C12Q1/02 ,  C07D311/30 ,  A61K49/00 ,  C07F9/6533 ,  C12N15/113 ,  G01N33/58 ,  A61K31/713

Abstract: This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-π, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.

公开(公告)号：US10047111B2

公开(公告)日：2018-08-14

申请号：US14979574

申请日：2015-12-28

Applicant: Nitto Denko Corporation

Inventor： Kenjirou Minomi ,  Hirokazu Takahashi ,  Erika Terada ,  Jens Harborth ,  Jun Zhang ,  Mohammad Ahmadian ,  Wenbin Ying

IPC: C12N15/113 ,  C07H21/02 ,  C07H21/04 ,  C07F9/6533 ,  C12Q1/02 ,  G01N33/58 ,  A61K31/713

Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

公开(公告)号：US10047110B2

公开(公告)日：2018-08-14

申请号：US14979567

申请日：2015-12-28

Applicant: Nitto Denko Corporation

Inventor： Kenjirou Minomi ,  Hirokazu Takahashi ,  Erika Terada ,  Jens Harborth ,  Jun Zhang ,  Mohammad Ahmadian ,  Wenbin Ying

IPC: C12N15/113 ,  C07H21/02 ,  C07F9/6533 ,  C12Q1/02 ,  G01N33/58 ,  A61K31/713

Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. A nucleic acid molecule can have a) a polynucleotide sense strand and a polynucleotide antisense strand; b) each strand of the molecule being from 15 to 30 nucleotides in length; c) a contiguous region of from 15 to 30 nucleotides of the antisense strand being complementary to a sequence of an mRNA encoding GST-π; and d) at least a portion of the sense strand can be complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length.

公开(公告)号：US09771582B2

公开(公告)日：2017-09-26

申请号：US14979566

申请日：2015-12-28

Applicant: Nitto Denko Corporation

Inventor： Yoshiro Niitsu ,  Kenjirou Minomi ,  Bharat Majeti ,  Li Wang ,  Jihua Liu ,  Roger Adami ,  Wenbin Ying

IPC: C07H21/04 ,  C12N15/113 ,  C07F9/6533 ,  C12Q1/02 ,  G01N33/58

CPC classification number: C07F9/6533 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/3515 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2320/35 ,  C12N2320/53 ,  C12Q1/02 ,  G01N33/582 ,  H05K999/99 ,  C12N2310/3533 ,  C12N2310/3531 ,  C12N2310/321 ,  C12N2310/3521

Abstract: This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-π, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.

公开(公告)号：US09695206B2

公开(公告)日：2017-07-04

申请号：US14979571

申请日：2015-12-28

Applicant: Nitto Denko Corporation

Inventor： Kenjirou Minomi ,  Jens Harborth ,  Cima Cina ,  Kwok Yin Tsang ,  Wenbin Ying ,  Hirokazu Takahashi

IPC: C12N15/11 ,  C07F9/6533 ,  C12N15/113 ,  C12Q1/02 ,  G01N33/58

CPC classification number: C07F9/6533 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/3515 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2320/35 ,  C12N2320/53 ,  C12Q1/02 ,  G01N33/582 ,  H05K999/99 ,  C12N2310/3533 ,  C12N2310/3531 ,  C12N2310/321 ,  C12N2310/3521

Abstract: This invention provides compounds, compositions and methods for modulating the expression of human p21 using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.